Modulation of Total Corneal Astigmatism, Corneal Thickness, and Corneal Higher-Order Aberrations Following Tear-Enhancing Drop Instillation: A Retrospective Comparative Study.

IF 4.2 3区医学 Q2 OPHTHALMOLOGY

Ophthalmology and Therapy Pub Date : 2026-10-01 Epub Date: 2026-08-14 DOI:10.1007/s40123-026-01472-4

Monika Sarnat-Kucharczyk, Aleksandra Ziemba, Anna Hitnarowicz, Ewa Mrukwa-Kominek, Sudi Patel

{"title":"Modulation of Total Corneal Astigmatism, Corneal Thickness, and Corneal Higher-Order Aberrations Following Tear-Enhancing Drop Instillation: A Retrospective Comparative Study.","authors":"Monika Sarnat-Kucharczyk, Aleksandra Ziemba, Anna Hitnarowicz, Ewa Mrukwa-Kominek, Sudi Patel","doi":"10.1007/s40123-026-01472-4","DOIUrl":null,"url":null,"abstract":"Introduction: This study aimed to quantify changes in corneal astigmatism, thickness, and corneal higher-order aberrations after instilling a tear-enhancing drop (Systane Hydration Ultra, SHU) or 0.9% saline.Methods: This retrospective comparative study included 56 eyes (SHU, n = 38; 0.9% saline, n = 18). Corneal pachymetry and optical parameters were assessed using CASIA2 swept-source anterior segment optical coherence tomography. Measurements were acquired immediately after a natural blink (baseline, time 0). Subsequently, one drop of SHU or 0.9% saline was instilled, and measurements were repeated at 5 and 10 min postinstillation.Results: No clinically relevant changes in mean total corneal astigmatism (TCA), apparent corneal thickness (CT), or corneal higher-order aberrations were observed following instillation of either SHU or 0.9% saline. On a case-by-case basis, changes observed in the 0.9% saline group correlated with preinstillation values. CT tended to reduce with saline and generally increase with SHU. The induced change in TCA (y) 10 min after instillation significantly correlated with preinstillation. (i) CT (t) in SHU cases, where y = 0.317-0.003t +0.006t2 (r2 = 0.361, n = 38, p < 0.001); and (ii) TCA (x) in 0.9% saline cases, where y = 0.68x-0.30 (r2 = 0.562, n = 18, p < 0.001). Overall, the induced change in TCA exceeded 0.50 D in 18% of SHU and 17% of 0.9% saline 10 min after instillation.Conclusions: Tear supplementation induces short-term case-specific changes in astigmatism and optical parameters, particularly within the first 5 min after Systane Hydration Ultra instillation. These findings may be relevant when interpreting corneal measurements in patients with mild ocular surface dysfunction undergoing refractive or cataract assessment.","PeriodicalId":19623,"journal":{"name":"Ophthalmology and Therapy","volume":" ","pages":"3317-3334"},"PeriodicalIF":4.2000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13546216/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmology and Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s40123-026-01472-4","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/8/14 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: This study aimed to quantify changes in corneal astigmatism, thickness, and corneal higher-order aberrations after instilling a tear-enhancing drop (Systane Hydration Ultra, SHU) or 0.9% saline.

Methods: This retrospective comparative study included 56 eyes (SHU, n = 38; 0.9% saline, n = 18). Corneal pachymetry and optical parameters were assessed using CASIA2 swept-source anterior segment optical coherence tomography. Measurements were acquired immediately after a natural blink (baseline, time 0). Subsequently, one drop of SHU or 0.9% saline was instilled, and measurements were repeated at 5 and 10 min postinstillation.

Results: No clinically relevant changes in mean total corneal astigmatism (TCA), apparent corneal thickness (CT), or corneal higher-order aberrations were observed following instillation of either SHU or 0.9% saline. On a case-by-case basis, changes observed in the 0.9% saline group correlated with preinstillation values. CT tended to reduce with saline and generally increase with SHU. The induced change in TCA (y) 10 min after instillation significantly correlated with preinstillation. (i) CT (t) in SHU cases, where y = 0.317-0.003t +0.006t² (r² = 0.361, n = 38, p < 0.001); and (ii) TCA (x) in 0.9% saline cases, where y = 0.68x-0.30 (r² = 0.562, n = 18, p < 0.001). Overall, the induced change in TCA exceeded 0.50 D in 18% of SHU and 17% of 0.9% saline 10 min after instillation.

Conclusions: Tear supplementation induces short-term case-specific changes in astigmatism and optical parameters, particularly within the first 5 min after Systane Hydration Ultra instillation. These findings may be relevant when interpreting corneal measurements in patients with mild ocular surface dysfunction undergoing refractive or cataract assessment.

查看原文本刊更多论文

泪液滴入后角膜总散光、角膜厚度和角膜高阶像差的调节：一项回顾性比较研究。

本研究旨在量化滴入促泪滴液（Systane Hydration Ultra， SHU）或0.9%生理盐水后角膜散光、厚度和角膜高阶像差的变化。方法：回顾性比较研究56只眼（SHU, n = 38； 0.9%生理盐水，n = 18）。采用CASIA2扫源前段光学相干断层扫描评估角膜厚度测量和光学参数。测量在自然眨眼后立即获得（基线，时间0）。随后，滴注1滴SHU或0.9%生理盐水，并在滴注后5和10分钟重复测量。结果：注射SHU或0.9%生理盐水后，平均角膜总散光（TCA）、角膜表观厚度（CT）或角膜高阶像差均无临床相关变化。在个案基础上，0.9%生理盐水组观察到的变化与注射前值相关。CT表现随生理盐水升高，随SHU升高。灌胃后10 min诱导的TCA (y)变化与灌胃前显著相关。(i) SHU病例的CT (t)，其中y = 0.317-0.003t +0.006t2 （r2 = 0.361, n = 38, p = 0.562, n = 18, p）结论：补充泪液可引起患者散光和光学参数的短期变化，特别是在系统stane Hydration Ultra注射后的前5分钟内。这些发现可能与解释轻度眼表功能障碍患者进行屈光或白内障评估时的角膜测量有关。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmology and Therapy OPHTHALMOLOGY-

CiteScore

4.20

自引率

3.00%

发文量

157

审稿时长

6 weeks

期刊介绍： Aims and Scope Ophthalmology and Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal. The scope of the journal is broad and will consider all scientifically sound research from preclinical, clinical (all phases), observational, real-world, and health outcomes research around the use of ophthalmological therapies, devices, and surgical techniques. The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials. Ophthalmology and Therapy will consider all scientifically sound research be it positive, confirmatory or negative data. Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations. This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals. Rapid Publication The journal’s publication timelines aim for a rapid peer review of 2 weeks. If an article is accepted it will be published 3–4 weeks from acceptance. The rapid timelines are achieved through the combination of a dedicated in-house editorial team, who manage article workflow, and an extensive Editorial and Advisory Board who assist with peer review. This allows the journal to support the rapid dissemination of research, whilst still providing robust peer review. Combined with the journal’s open access model this allows for the rapid, efficient communication of the latest research and reviews, fostering the advancement of ophthalmic therapies. Open Access All articles published by Ophthalmology and Therapy are open access. Personal Service The journal’s dedicated in-house editorial team offer a personal “concierge service” meaning authors will always have an editorial contact able to update them on the status of their manuscript. The editorial team check all manuscripts to ensure that articles conform to the most recent COPE, GPP and ICMJE publishing guidelines. This supports the publication of ethically sound and transparent research. Digital Features and Plain Language Summaries Ophthalmology and Therapy offers a range of additional features designed to increase the visibility, readership and educational value of the journal’s content. Each article is accompanied by key summary points, giving a time-efficient overview of the content to a wide readership. Articles may be accompanied by plain language summaries to assist readers who have some knowledge of, but not in-depth expertise in, the area to understand the scientific content and overall implications of the article. The journal also provides the option to include various types of digital features including animated abstracts, video abstracts, slide decks, audio slides, instructional videos, infographics, podcasts and animations. All additional features are peer reviewed to the same high standard as the article itself. If you consider that your paper would benefit from the inclusion of a digital feature, please let us know. Our editorial team are able to create high-quality slide decks and infographics in-house, and video abstracts through our partner Research Square, and would be happy to assist in any way we can. For further information about digital features, please contact the journal editor (see ‘Contact the Journal’ for email address), and see the ‘Guidelines for digital features and plain language summaries’ document under ‘Submission guidelines’. For examples of digital features please visit our showcase page https://springerhealthcare.com/expertise/publishing-digital-features/ Publication Fees Upon acceptance of an article, authors will be required to pay the mandatory Rapid Service Fee of €5250/$6000/£4300. The journal will consider fee discounts and waivers for developing countries and this is decided on a case by case basis. Peer Review Process Upon submission, manuscripts are assessed by the editorial team to ensure they fit within the aims and scope of the journal and are also checked for plagiarism. All suitable submissions are then subject to a comprehensive single-blind peer review. Reviewers are selected based on their relevant expertise and publication history in the subject area. The journal has an extensive pool of editorial and advisory board members who have been selected to assist with peer review based on the afore-mentioned criteria. At least two extensive reviews are required to make the editorial decision, with the exception of some article types such as Commentaries, Editorials, and Letters which are generally reviewed by one member of the Editorial Board. Where reviewer recommendations are conflicted, the editorial board will be contacted for further advice and a presiding decision. Manuscripts are then either accepted, rejected or authors are required to make major or minor revisions (both reviewer comments and editorial comments may need to be addressed). Once a revised manuscript is re-submitted, it is assessed along with the responses to reviewer comments and if it has been adequately revised it will be accepted for publication. Accepted manuscripts are then copyedited and typeset by the production team before online publication. Appeals against decisions following peer review are considered on a case-by-case basis and should be sent to the journal editor. Preprints We encourage posting of preprints of primary research manuscripts on preprint servers, authors’ or institutional websites, and open communications between researchers whether on community preprint servers or preprint commenting platforms. Posting of preprints is not considered prior publication and will not jeopardize consideration in our journals. Authors should disclose details of preprint posting during the submission process or at any other point during consideration in one of our journals. Once the manuscript is published, it is the author’s responsibility to ensure that the preprint record is updated with a publication reference, including the DOI and a URL link to the published version of the article on the journal website. Please follow the link for further information on preprint sharing: https://www.springer.com/gp/authors-editors/journal-author/journal-author-helpdesk/submission/1302#c16721550 Copyright Ophthalmology and Therapy''s content is published open access under the Creative Commons Attribution-Noncommercial License, which allows users to read, copy, distribute, and make derivative works for non-commercial purposes from the material, as long as the author of the original work is cited. The author assigns the exclusive right to any commercial use of the article to Springer. For more information about the Creative Commons Attribution-Noncommercial License, click here: http://creativecommons.org/licenses/by-nc/4.0. Contact For more information about the journal, including pre-submission enquiries, please contact christopher.vautrinot@springer.com.